Register to Download SmartTRAK's Perspective Article
Charlie Covert, VP/GM of Medtronic’s Pain Therapies business discusses
12-month data from the Company’s Differential Targeted Multiplexed
(DTM) SCS RCT, why they used a modified intent to treat analysis (mITT)
and what’s next for DTM research in an interview with SmartTRAK. To find out more about DTM SCS, including its mechanism of action, how it’s doing in the market and Medtronics’ research into expanded indications and new technologies, register to read now!
